Literature DB >> 11965026

Localized interleukin-10 gene transfer induces apoptosis of alloreactive T cells via FAS/FASL pathway, improves function, and prolongs survival of cardiac allograft.

Kiyohiro Oshima1, Luyi Sen, Guanggen Cui, Thomas Tung, Benjamin M Sacks, Anthony Arellano-Kruse, Hillel Laks.   

Abstract

We hypothesized that localized IL-10 gene transfer can induce alloreactive T cell apoptosis and tested this hypothesis with liposome-mediated ex vivo intracoronary IL-10 gene transfer using a functional heterotopic allograft heart transplant model in rabbits. Localized IL-10 overexpression prolonged cardiac allograft survival over three folds. In parallel with the time-course of IL-10 overexpression, the percentage of apoptotic CD3+ cells among total CD3+ cells was significantly increased in the gene therapy group (36.5+/-3.9%) compared with that in the control group (6.2+/-2.6%, P<0.01) on postoperative day (POD) 3-6, and it was further increased (45.8+/-5.7%) on POD7-10. Apoptotic CD4+ and CD8+ cells were also significantly increased in the gene group (P<0.01). In contrast, the percentage of apoptotic myocytes significantly decreased from 10.1+/-0.8% in the control group to 3.5+/-0.4% in the gene group on POD7-10 (P<0.01). This reduction was inversely correlated with the increase in the percentages of apoptotic CD4+ and CD8+ cells (P<0.01). The percentage of caspase-3 positive myocytes was significantly reduced, although percentages of caspase-3 positive CD4+ and CD8+ cells were markedly increased in the gene group (P<0.01). Moreover, about 60-80% of apoptotic T lymphocytes expressed Fas in the gene group compared with less than 10% in the control group (P<0.01). These results suggest that localized IL-10 gene transfer induces alloreactive T cell apoptosis via the Fas/FasL pathway that may contribute to the alleviated acute rejection, improved cardiac function, and prolonged survival in the IL-10 gene-treated cardiac allografts.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11965026     DOI: 10.1097/00007890-200204150-00002

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  7 in total

1.  Prolongation of heart allograft survival after long-term expression of soluble MHC class I antigens and vIL-10 in the liver by AAV-plasmid-mediated gene transfer.

Authors:  A Doenecke; E Frank; M N Scherer; H-J Schlitt; E K Geissler
Journal:  Langenbecks Arch Surg       Date:  2008-03-06       Impact factor: 3.445

Review 2.  Lung transplantation: infection, inflammation, and the microbiome.

Authors:  Takeshi Nakajima; Vyachesav Palchevsky; David L Perkins; John A Belperio; Patricia W Finn
Journal:  Semin Immunopathol       Date:  2011-01-27       Impact factor: 9.623

3.  IL-10/Janus kinase/signal transducer and activator of transcription 3 signaling dysregulates Bim expression in autoimmune lymphoproliferative syndrome.

Authors:  Omar Niss; Allyson Sholl; Jack J Bleesing; David A Hildeman
Journal:  J Allergy Clin Immunol       Date:  2014-08-28       Impact factor: 10.793

Review 4.  Treatment of Type 1 diabetes with anti-CD3 monoclonal antibody: induction of immune regulation?

Authors:  Kevan C Herold; Lesley Taylor
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

5.  Reactive oxygen and reactive nitrogen as signaling molecules for caspase 3 activation in acute cardiac transplant rejection.

Authors:  Galen M Pieper; Vani Nilakantan; Thanh K Nguyen; Gail Hilton; Allan M Roza; Christopher P Johnson
Journal:  Antioxid Redox Signal       Date:  2008-06       Impact factor: 8.401

6.  Soluble mediators from mesenchymal stem cells suppress T cell proliferation by inducing IL-10.

Authors:  Seung-Ha Yang; Min-Jung Park; Il-Hee Yoon; Su-Young Kim; So-Hee Hong; Jin-Young Shin; Hye-Young Nam; Yong-Hee Kim; Bongi Kim; Chung-Gyu Park
Journal:  Exp Mol Med       Date:  2009-05-31       Impact factor: 8.718

Review 7.  Cytolytic CD4+ and CD8+ Regulatory T-Cells and Implications for Developing Immunotherapies to Combat Graft-Versus-Host Disease.

Authors:  Sara Bolivar-Wagers; Jemma H Larson; Sujeong Jin; Bruce R Blazar
Journal:  Front Immunol       Date:  2022-04-12       Impact factor: 8.786

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.